Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ:CVKDHealthcare · Biotechnology
-5.21%$0.9100
AH Close$0.9100+0.00%vs close
AH Close$0.9100+0.00%vs close
Mkt Cap$3.25M
Float3.05M
O/S3.57M
Inst Own3.8%
SI9.2%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$13.24M
Total Assets$4.33M
Free Cash Flow-$12.6M
Debt & Equity
Equity 100%
Total Debt$0
Total Equity$2.74M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:15Reverse splitAug 20, 202415 shares → 1
Balance Sheet Details
Assets$4.33M
Liabilities$1.59M
Accounts Receivable$5K
Accounts Payable$651K
Inventory$0
PP&E (Net)$5K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Revenue | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $1K |
| Gross Profit | $0 | $0 | $0 | -$1K |
| Gross Margin | - | - | - | - |
| Research and Development | $4.1M | $4.21M | $4.08M | $393K |
| Selling, General, and Administrative | $9.35M | $6.75M | $3.55M | $2.31M |
| Other | $7K | $2K | $2K | $0 |
| Total Operating Expenses | $13.46M | $10.96M | $7.63M | $2.7M |
| Operating Income (EBIT) | -$13.46M | -$10.96M | -$7.63M | -$2.7M |
| Operating Margin | - | - | - | - |
| Interest Expense | $0 | $0 | $17K | $107K |
| Interest Income | $224K | $309K | $249K | $0 |
| Other Income (Expense) | $224K | $309K | -$724K | -$4.01M |
| Income Before Tax (EBT) | -$13.24M | -$10.65M | -$8.36M | -$6.71M |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$13.24M | -$10.65M | -$8.36M | -$6.71M |
| Net Income Margin | - | - | - | - |
| Supplementary Data | ||||
| EPS | -6.64 | -8.73 | -9.63 | -8.66 |
| Diluted EPS | -6.64 | -8.73 | -9.63 | -8.66 |
| Weighted Average OS | 1.99M | 1.22M | 868,183 | 775,638 |
| EBITDA | -$13.23M | -$10.65M | -$8.34M | -$6.61M |
| EBITDA Margin | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $4.01M | $10.02M | $8.4M | $33K |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $4.01M | $10.02M | $8.4M | $33K |
| Accounts Receivable | $5K | $38K | $37K | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Current Assets | $306K | $14K | $0 | $672K |
| Total Current Assets | $4.32M | $10.11M | $8.49M | $728K |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $5K | $7K | $23K | $45K |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $532K |
| Other Long-Term Assets | $2K | $4K | $4K | -$526K |
| Total Long-Term Assets | $7K | $11K | $27K | $51K |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $4.33M | $10.12M | $8.52M | $778K |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $651K | $1.5M | $167K | $405K |
| Short-Term Debt | $0 | $0 | $0 | $44K |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $733K | $967K | $596K | $605K |
| Total Current Liabilities | $1.59M | $2.68M | $827K | $1.33M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $0 | $0 | $0 | $553K |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $4.42M |
| Total Long-Term Liabilities | $0 | $0 | $0 | $4.99M |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.59M | $2.68M | $827K | $6.33M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $0 | $0 | $0 |
| Common Stock | $2K | $2K | $13K | $8K |
| Retained Earnings | -$38.96M | -$25.72M | -$15.07M | -$6.71M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $41.7M | $33.16M | $22.75M | $1.15M |
| Total Equity | $2.74M | $7.44M | $7.69M | -$5.55M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $4.33M | $10.12M | $8.52M | $778K |
| Supplementary Data | ||||
| Total Debt | $0 | $0 | $21K | $641K |
| Net Debt | -$4.01M | -$10.02M | -$8.38M | $608K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$13.24M | -$10.65M | -$8.36M | -$7.32M |
| Depreciation & Amortization | $7K | $2K | $2K | $1K |
| Deferred Income Tax | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $1.94M | $1.42M | $710K | $1.01M |
| Changes in Working Capital: | ||||
| Accounts Receivable | $33K | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Accounts Payable | -$852K | $1.34M | -$238K | $0 |
| Other Working Capital | -$492K | $538K | $382K | $221K |
| Total Working Capital Change | -$1.31M | $1.87M | $144K | $221K |
| Other Non-Cash Items | $0 | -$352 | $3.97M | $4.78M |
| Net Cash from Operating | -$12.6M | -$7.36M | -$3.53M | -$1.31M |
| Investing Activities | ||||
| Capital Expenditures | -$5K | -$7K | -$3K | -$2K |
| Acquisitions | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$5K | -$7K | -$3K | -$2K |
| Financing Activities | ||||
| Debt Repaid | - | - | - | - |
| Common Stock Issuance | $7.16M | $5.14M | $11.9M | $0 |
| Common Stock Repurchases | -$292K | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$271K | $3.84M | $250K | $1.35M |
| Net Cash from Financing | $6.6M | $8.98M | $11.9M | $1.35M |
| Forex Effect | $0 | $0 | $0 | -$3K |
| Net Change in Cash | -$6.01M | $1.62M | $8.37M | $33K |
| Supplementary Data | ||||
| Operating Cash Flow | -$12.6M | -$7.36M | -$3.53M | -$1.31M |
| Capital Expenditure | -$5K | -$7K | -$3K | -$2K |
| Free Cash Flow | -$12.6M | -$7.36M | -$3.53M | -$1.32M |
| Cash at Beginning | $10.02M | $8.4M | $33K | $0 |
| Cash at End | $4.01M | $10.02M | $8.4M | $33K |